Eye Diseases clinical trials
The registry lists 388 studies for Eye Diseases across more than 10 countries. 62 are recruiting or about to start. 103 of them are mainly about Eye Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 125 narrower conditions too, such as Cataract: 15,770 studies, 2,631 open.
Get an email when these change. Save the Eye Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Eye Institute (NEI) (18) · Novartis Pharmaceuticals (10) · Sun Yat-sen University (10) · Zhongshan Ophthalmic Center, Sun Yat-sen University (9) · GenSight Biologics (8) · Glaukos Corporation (8) · Adverum Biotechnologies, Inc. (8) · University of California, San Francisco (8)
What is being tested here
Drugs under test in Eye Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Acoltremon | 3 | 0 | 3 |
| Atropine | 2 | 1 | 2 |
| Sepofarsen | 1 | 3 | 4 |
| Linsitinib | 1 | 2 | 2 |
| Tissue Plasminogen Activator | 1 | 1 | 1 |
| Dapagliflozin | 1 | 0 | 1 |
| Fusidic Acid | 1 | 1 | 1 |
| Aceclidine | 0 | 4 | 7 |
| Ranibizumab | 0 | 2 | 7 |
| Tarcocimab tedromer | 0 | 6 | 6 |
Drug classes tested here Antimuscarinics 2 open · Tyrosine kinase inhibitors (TKIs) 1 open · Angiogenesis inhibitors 11 · Corticosteroids 6
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD · Phase 3 · AbbVie
- Dec 2026Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration · Phase 3 · Adverum Biotechnologies, Inc.
- Nov 2027Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) · Phase 3 · Laboratoires Thea
- Nov 2027Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) · Phase 3 · Adverum Biotechnologies, Inc.
- Dec 2026A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma · Iantrek, Inc.
- Dec 2026Characterization of Potential Biomarkers of Eye Disease and Vision · Association for Innovation and Biomedical Research on Light and Image
- Dec 2026Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting · Universiti Kebangsaan Malaysia Medical Centre
- Dec 2026Does Orientation On Eye Health To Female Health Volunteers Increase Footfall In A Vision Center · Seva Canada Society
- Feb 2027Promising ROd-cone DYstrophy Gene therapY · SparingVision
- Mar 2027Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa · University Hospital Tuebingen
Who these studies take
Of the 53 Eye Diseases studies recruiting now, 36 (68%) set no upper age limit and 8 (15%) stop at 75 or younger. 22 (42%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 19 (36%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 17 (32%) | 17 (32%) |
| 18 | 39 (74%) | 39 (74%) |
| 30 | 38 (72%) | 38 (72%) |
| 40 | 38 (72%) | 38 (72%) |
| 50 | 44 (83%) | 44 (83%) |
| 65 | 46 (87%) | 46 (87%) |
| 75 | 46 (87%) | 46 (87%) |
| 85 | 44 (83%) | 44 (83%) |
Across all 388 studies, recruiting or not: 21% stop at 75 or younger and 15% at 65; 31% take children; 1% are for women only and 1% for men only; 28% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Eye Diseases studies take
Of 28 phase 3 interventional studies under Eye Diseases, half reached primary completion within 25 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 25 mo15–51 · 16 studies | — | — |
| Phase 2 | 19 mo12–29 · 24 studies | — | — |
| Phase 3 | 25 mo20–39 · 28 studies | — | — |
| Phase 4 | 30 mo27–67 · 13 studies | — | — |
| Interventional, no phase | 24 mo9–49 · 68 studies | — | 24 mo8–45 · 49 studies |
| Observational | 41 mo11–86 · 52 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Stopped1
- Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With KeratoconusTerminatedNov 5, 2026NCT06601101
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 388. Browse all 388 → or search them.
- A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).RecruitingNCT07867080Phase 34 countries
- Adaptive Optics Retinal ImagingRecruitingNCT023173281 country
- Screening for Research ParticipantsRecruitingNCT006550961 country
- Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye DiseaseRecruitingNCT07885605Phase 11 country
- Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)RecruitingNCT06891443Phase 310 countries
- Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAIONRecruitingNCT05147701Phase 12 countries
- Natural History, Pathogenesis, and Outcome of Ocular DisordersRecruitingNCT028217671 country
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)RecruitingNCT07482176Phase 31 country
- A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)RecruitingNCT07408232Phase 1/21 country
- Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve CareRecruitingNCT07738874Not applicable1 country
- Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).RecruitingNCT04663750Phase 37 countries
- Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone DystrophyRecruitingNCT07807111Phase 1/23 countries
- Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)RecruitingNCT07002398Phase 1/21 country
- SGLT2 Inhibitors in Geographic AtrophyRecruitingNCT07174687Phase 21 country
- Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular DegenerationRecruitingNCT07630649Phase 21 country
- APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical EyesRecruitingNCT07434635Phase 41 country
- Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry EyeRecruitingNCT07413172Phase 21 country
- Ocular Blood Flow Imaging for Glaucoma AssessmentRecruitingNCT05726058Not applicable1 country
- Stem Cell Ophthalmology Treatment Study IIRecruitingNCT03011541Not applicable3 countries
- The Proactive Ophthalmic Examination CohortRecruitingNCT058512871 country
- Assessing Agreement Between Acuvera Capture and Paper-Based Methods for BCVA Data Recording in Ophthalmic TrialsRecruitingNCT076135801 country
- Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual PerformanceRecruitingNCT075489441 country
- Does Orientation On Eye Health To Female Health Volunteers Increase Footfall In A Vision CenterRecruitingNCT07443683Not applicable1 country
- Strategies for Improving Linkage-to-Care After Eye Disease ScreeningRecruitingNCT06943599Not applicable1 country
- Natural History Study of Patients With EYS-Associated RPRecruitingNCT072287931 country
- The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston KeratoprosthesisRecruitingNCT04232982Not applicable1 country
- RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)RecruitingNCT07322302Not applicable2 countries
- Advancing Pediatric Retinal Imaging With Auto-aligned OCTRecruitingNCT06841575Not applicable1 country
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial ConjunctivitisRecruitingNCT06911424Phase 31 country
- Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON PatientsRecruitingNCT07303296Phase 21 country
- A Multimodal AI Agent for Ophthalmic Clinical Decision SupportNot yet recruitingNCT07401459Not applicable1 country
- Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)RecruitingNCT07028827Phase 35 countries
- Effectiveness of a Large Language Model-Based Educational Tool on Visual Field Test Reliability in Glaucoma PatientsEnrolling by invitationNCT07327242Not applicable1 country
- Effectiveness of a Large Language Model-Based Educational Tool on Intraocular Lens OptionsEnrolling by invitationNCT07317661Not applicable1 country
- Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2RecruitingNCT06934577Not applicable1 country
- Switching From Restasis to TRYPTYRNot yet recruitingNCT07267299Phase 4
- Switching From Xiidra to TRYPTYRNot yet recruitingNCT07267481Phase 4
- Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform WorkRecruitingNCT07266948Phase 41 country
- Clinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia ProgressionRecruitingNCT06850168Not applicable1 country
- Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical SettingRecruitingNCT05694858Phase 1/21 country
- Dry Eye in Upper Eyelid Surgery: Muscle Versus Fat RemovalEnrolling by invitationNCT06985264Not applicable1 country
- Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 GeneRecruitingNCT06291935Phase 11 country
- Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)RecruitingNCT06112340Phase 2/31 country
- Virtual Reality and Its Use in Reducing Perioperative Stress in Cataract SurgeryNot yet recruitingNCT06822023Not applicable
- Patterns of Eye Diseases Among Patients Attending The Eye Investigation Unit of Sohag University HospitalRecruitingNCT068128451 country
- Co-designing and Evaluating a Real-world Implementation Model for Remote Consultation with Vision Self-testing.RecruitingNCT059411821 country
- Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding GenomesRecruitingNCT067755611 country
- THE ROLE OF HEXAMIDINE DIISETHIONATE (ZAMIDINE®) 1MG/ML 0.6ML EYE DROPS IN THE PROPHYLAXIS OF SURGERY OFTALMICRecruitingNCT067719081 country
- Development of a Deep Learning System for Identification of Neuro-Ophthalmological Conditions on Color Fundus Photographs in Emergency DepartmentRecruitingNCT066433381 country
- Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.RecruitingNCT06394232Phase 1/21 country